Glykosyliertes Fusionsprotein, Nukleinsäuremolekül, Expressionsvektor, Wirtszelle und Verwendung davon

Details

Veröffentlichungs-Nr.

EP4789681

Anmeldetag

28. August 2025

Veröffentlichung

25. Juni 2026

Rechtsraum

EP

Abstract

The present application provides a glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell and applications thereof. A first aspect of the present application provides a glycosyl-modified fusion protein, including a murine Fc variant and a hepatitis B virus antigen, where the murine Fc variant is obtained by subjecting a murine Fc fragment to amino acid mutation and non-mammalian glycosylation modification; the murine Fc variant includes at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332; the glycosylation modification does not include sialic acid modification; the numbering of position is performed according to EU numbering system. The fusion protein is capable of binding to and activating DCs and promoting proliferation and activation of specific T cells.

Anmelder

Firma

Chimigen Biomedical (Chengdu) Co., Ltd.

Land

🇨🇳 China